SMO and cancer: Mechanistically, GLI1 is phosphorylated and activated in a SMO-independent manner by MAPK-ERK1/2 signaling, that can be induced by KRAS or through stimulation of Neuropilin 2 receptor by its ligand VEGFA, secreted by cancer cells in an autocrine loop or by stromal cells in a paracrine manner.